Judo Bio's Revolutionary Approach to Kidney Medicine
Judo Bio, a forward-thinking biotechnology firm, is making waves in the world of therapeutics by developing groundbreaking oligonucleotide medicines specifically geared for the kidney. Their focus on receptor-mediated delivery positions them at the forefront of renal healthcare. Recently, they announced their participation in a significant scientific event, showcasing promising preclinical data related to their innovative technology.
The Power of Megalin Receptors
At the upcoming American Society of Nephrology (ASN) Kidney Week, Judo Bio will present compelling mechanistic insights into their therapeutic approach. The spotlight will be on how they utilize megalin receptors to facilitate the intracellular delivery of ligand-conjugated siRNA therapeutics. This method effectively silences target mRNA production right within the kidney cells.
Key Presentation Details
Judo Bio has announced that their poster titled "Targeted Delivery of siRNA to Proximal Tubule Cells in Kidney" will be featured during the event. Attendees can look forward to a detailed exploration of their findings:
Session Name: Genetic Kidney Diseases: Models, Mechanisms, and Therapies [PO1202-3]
Session Date and Time: October 26 from 10:00 a.m. to 12:00 p.m. PT
Location: San Diego Convention Center, Exhibit Hall
Poster Number: SA-PO637
Understanding Judo Bio's STRIKE Platform
Judo Bio's platform, known as STRIKE (Selectively Targeting RNA Into KidnEy), represents a distinctive method of creating ligand-RNA conjugate drugs tailored for renal cell receptors. This proprietary approach is crucial for developing innovative genetic medicines intended to combat systemic and kidney-specific diseases. Their commitment to advancing gene silencing through precise receptor targeting is paving the way for new treatments.
Focusing on Kidney Health
By targeting the proximal tubule of the kidney, Judo Bio aims to silence mRNA expressions of solute carrier proteins (SLCs) through their megalin-STRIKER programs. This strategy is essential for mitigating the uptake of circulating solutes, which can be linked to systemic health issues. The importance of addressing such solutes lies not only in improving kidney function but also in potentially alleviating broader health concerns.
About Judo Bio
Located in Cambridge, MA, Judo Bio boasts a team comprising influencers and experts in the realm of oligonucleotide therapies and advanced drug development. Their work in the field makes them a key player in the biopharmaceutical landscape. For those interested in learning more about their innovative approaches and ongoing projects, Judo Bio encourages visiting their official website and following them on LinkedIn.
Frequently Asked Questions
What is Judo Bio's primary focus?
Judo Bio focuses on developing oligonucleotide medicines delivered specifically to the kidney.
What technology does Judo Bio utilize for their therapeutics?
They use their proprietary STRIKE platform for the targeted delivery of siRNA to kidney cells.
When is Judo Bio's presentation at the ASN Kidney Week?
The presentation is scheduled for October 26, from 10:00 a.m. to 12:00 p.m. PT.
Where will the ASN Kidney Week event take place?
The event will occur at the San Diego Convention Center.
How can I find more information about Judo Bio?
More information can be found on their website and their LinkedIn profile.